Skip to main content
Clinical Trials/NCT06039917
NCT06039917
Recruiting
Not Applicable

Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions

Renmin Hospital of Wuhan University4 sites in 1 country1,460 target enrollmentSeptember 10, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Artificial Intelligence
Sponsor
Renmin Hospital of Wuhan University
Enrollment
1460
Locations
4
Primary Endpoint
On-time Surveillance Rate
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of patients with gastric premalignant lesions. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups will be compared.

Detailed Description

The adherence of doctors to published surveillance guidelines for patients with gastric premalignant lesions varies greatly, and surveillance of patients is critical but time-consuming. In previous studies we developed an automatic surveillance (AS) system to accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients in time. In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of patients with gastric premalignant lesions. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups will be compared.

Registry
clinicaltrials.gov
Start Date
September 10, 2023
End Date
December 31, 2029
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female aged 18 years or older who undergo upper endoscopy.

Exclusion Criteria

  • No contact information or invalid contact information.
  • The surveillance interval cannot be determined according to the surveillance guidelines, including no upper gastrointestinal pathology, therapeutic endoscopy or with history of previous gastrectomy, esophagectomy, or ESD, no dysplasia degrees, no biopsy sites, non-epithelial lesions, duodenal lesions, ulcer and so on.
  • Needless for surveillance or others.
  • High-grade intraepithelial neoplasia or cancer of the esophagus or stomach.
  • Low-grade intraepithelial neoplasia of the esophagus and Barrett's esophagus.
  • High-risk diseases or other special conditions for which the patient is deemed unsuitable for clinical trials by the investigator.

Outcomes

Primary Outcomes

On-time Surveillance Rate

Time Frame: From enrollment to study completion, assessed up to 3 years.

The numerator is the number of patients with on-time surveillance, and the denominator is the number of all patients with gastric premalignant lesions requiring surveillance.

Secondary Outcomes

  • lesion regression rate(From enrollment to study completion, assessed up to 3 years.)
  • Surveillance Rate(From enrollment to study completion, assessed up to 3 years.)
  • The accuracy of classifying risk levels(1 day At the time of enrollment)
  • The incidence rate of early gastric cancer(From enrollment to study completion, assessed up to 3 years.)
  • The incidence rate of gastric cancer(From enrollment to study completion, assessed up to 3 years.)
  • The accuracy of identifying patients with gastric premalignant lesions(1 day At the time of enrollment)
  • The accuracy of assigning surveillance intervals(1 day At the time of enrollment)
  • Delayed Surveillance Rate(From enrollment to study completion, assessed up to 3 years.)
  • lesion persistence rate(From enrollment to study completion, assessed up to 3 years.)
  • Advance Surveillance Rate(From enrollment to study completion, assessed up to 3 years.)
  • lesion progression rate(From enrollment to study completion, assessed up to 3 years.)

Study Sites (4)

Loading locations...

Similar Trials